AMARIN CORP PLCUK
AMRN evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $291.8M
- Lead Asset:
- vascepa (Approved)
What it means
What to watch
Prepared research question
What matters most for AMRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMRN
Amarin Corporation PLC is a pharmaceutical company focused on cardiovascular therapeutics, primarily commercializing VASCEPA/VAZKEPA (icosapent ethyl) for triglyceride reduction and cardiovascular risk reduction, with a fully partnered global commercial model outside the U.S.
Key risk: Generic erosion of VASCEPA
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 catalyst for AMARIN CORP PLCUK.
Amarin Corporation PLC is a pharmaceutical company focused on cardiovascular therapeutics, primarily commercializing VASCEPA/VAZKEPA (icosapent ethyl) for triglyceride reduction and cardiovascular risk reduction, with a fully partnered global commercial model outside the U.S.
- Amarin's sole marketed product is VASCEPA (icosapent ethyl), approved in the U.S. since July 2012 for severe hypertriglyceridemia and for cardiovascular risk reduction in select high-risk patients [pipeline].
- In 2025, Amarin executed an exclusive license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA in 59 European countries, resulting in a fully partnered model outside the U.S. [sec · filed 2026-04-10].
- As of 2026-06-30, Amarin reported cash & equivalents of $143.6M, total revenue of $42.2M, net income of -$7.7M, shareholders' equity of $443.6M, and no debt [sec].
- The company faces generic competition for icosapent ethyl from multiple manufacturers including Hikma, Dr. Reddy's, Teva, Apotex, Zydus, and others [pipeline].
- Amarin has a share repurchase program authorized for up to $50.0 million through the second quarter of 2029, though no repurchases have been made as of late 2025 [sec_mda · as of 2025-10-29].
What works
- Amarin has no debt and a cash position of $143.6M as of 2026-06-30, providing financial flexibility [sec].
- The Recordati licensing deal restructured Amarin's European operations, improving capital efficiency and preserving participation in future international growth without direct commercial costs [sec · filed 2026-04-10].
- VASCEPA/VAZKEPA is approved in multiple major markets (U.S., EU, UK) for both severe hypertriglyceridemia and cardiovascular risk reduction, supported by the REDUCE-IT trial [pipeline][sec_mda · as of 2026-03-02].
What to weigh
- Amarin faces significant generic competition for icosapent ethyl from at least nine manufacturers, which pressures U.S. market share and pricing [pipeline].
- The company reported a net loss of $7.7M for the six months ended 2026-06-30, indicating ongoing unprofitability [sec].
- Amarin's key patent for icosapent ethyl (NDA202057) is set to expire on 2033-06-28, which could further erode exclusivity and revenue [upcoming catalysts].
- The company's revenue of $42.2M for the first half of 2026 is relatively modest, reflecting the impact of generic erosion and the transition to a partnered model [sec].
From the filings
Quoted directly from source documents.
Amarin's sole marketed product is VASCEPA (icosapent ethyl), approved for severe hypertriglyceridemia and cardiovascular risk reduction.
“Our commercialized product, VASCEPA ® (icosapent ethyl) was first approved by the United States, or U.S., Food and Drug Administration, or U.S. FDA, in July 2012 for use as an adjunct to diet to reduce trig”
SEC MD&A · March 2, 2026
Amarin entered a licensing agreement with Recordati for European commercialization in 2025.
“In 2025, Amarin executed an exclusive license and supply agreement with Recordati S.p.A. ( "Recordati" ) to commercialize VAZKEPA® in 59 countries, focused in Europe.”
SEC filings · April 10, 2026
Generic competition for icosapent ethyl exists from multiple manufacturers.
“Competitive Landscape: Generic versions of icosapent ethyl from Hikma, Dr. Reddy's, Teva, Apotex, Zydus, Amneal, Epic Pharma, Camber, and Xiamen LP Pharma.”
Catalyst timeline
- 2033-06-28 · Patent_Expiry · ICOSAPENT ETHYL — Patent_Expiry: NDA202057 — Expiration of the key patent for icosapent ethyl could open the door to full generic competition, significantly impacting Amarin's revenue.
Risks & what to watch (4)›
Key risks
- Generic erosion of VASCEPA — Multiple generic entrants for icosapent ethyl pressure U.S. revenue and market share [pipeline].
- Patent expiry in 2033 — Key patent for icosapent ethyl expires on 2033-06-28, potentially ending exclusivity [upcoming catalysts].
- Ongoing net losses — Net loss of $7.7M in first half of 2026 indicates continued unprofitability [sec].
- Dependence on single product — Amarin's entire revenue depends on VASCEPA/VAZKEPA, with no other approved products [pipeline].
What to watch
- U.S. revenue trends amid generic competition for icosapent ethyl [pipeline].
- Progress of Recordati's European launch and milestone payments from the licensing deal [sec · filed 2026-04-10].
- Cash burn rate and path to profitability given net losses [sec].
- Any potential authorized generic launch by Amarin in the U.S. [sec · filed 2025-04-10].
Sources: Pipeline · SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run AMARIN CORP PLCUK through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AMARIN CORP PLCUK facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.41 · 0% dilution
Lead: Approved
3 candidates
1 upcoming, next in ~2448d
No insider transactions in the last 180 days
Catalysts
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 3.3%
- Days to cover
- 10.3
- Shares short
- 673,967
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMRN short interestGovernance
Frequently asked questions
What is the AI investment thesis for AMARIN CORP PLCUK?
Amarin Corporation PLC is a pharmaceutical company focused on cardiovascular therapeutics, primarily commercializing VASCEPA/VAZKEPA (icosapent ethyl) for triglyceride reduction and cardiovascular risk reduction, with a fully partnered global commercial model outside the U.S.
What is AMARIN CORP PLCUK's lead drug candidate?
AMARIN CORP PLCUK's most advanced tracked candidate is vascepa (Approved) for Reducing triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia; reducing persistent cardiovascular risk in select high-risk patients as an adjunct to maximally tolerated statin therapy..
What is AMARIN CORP PLCUK's next catalyst?
AMARIN CORP PLCUK's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA202057" — expected June 28, 2033.
Who is the CEO of AMARIN CORP PLCUK?
Mr. Aaron D. Berg is the chief executive officer of AMARIN CORP PLCUK (AMRN).
Where is AMARIN CORP PLCUK headquartered?
AMARIN CORP PLCUK (AMRN) is headquartered in Dublin, Ireland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.